Stock Taper
SCREENER COMPARE ANY 2 STOCKS
AKTX
AKARI THERAPEUTICS, PLC
NASDAQ
$10.70
▲ UP 18.76% (1.69)

KEY STATISTICS

Market Cap$12.25 M
52w High$49.60
52w Low$3.02
Dividend Yield—
Frequency—
P/E-2.39
Volume168.08K
Shares Out.1.14M

COMPANY

LEADERSHIP

Abizer Gaslightwala
CHIEF EXECUTIVE
Abizer Gaslightwala

COMPENSATION 2026

Salary$357,292
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$0
Total$7,306,951

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 6, 2014
METHOD OF GOING PUBLIC
Reverse Merger
FULL TIME EMPLOYEES
6

PRICE TARGET

Target High$30.00
Target Low$30.00
Target Median$30.00
Target Consensus$30.00

UPCOMING EARNINGS

DateDec 4, 2026
DayFriday
Rev. Est.—
DEC
4
FRI

SPLIT RECORD

DATETYPERATIO
2026-03-31Reverse1:40
2023-08-21Reverse1:20
2023-08-17Reverse1:20
2015-09-17Reverse1:10
2014-01-08Reverse1:5
2014-01-03Reverse1:5

PRICE

$10.70 ▲ UP 18.76% (+$1.69)
OVERLAYS
$9.00$9.75$10.50$11.259:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM10.70

About Akari Therapeutics, Plc

https://www.akaritx.com ↗

Akari Therapeutics, Plc is a London-based clinical-stage biopharmaceutical company developing therapies like nomacopan for autoimmune and inflammatory diseases such as PNH, Guillain-Barré, and thrombotic microangiopathy.

INDUSTRY

Biotechnology

A PRODUCT AKARI THERAPEUTICS, PLC IS KNOWN FOR

AKTX-101
AKTX-101

AKTX-101 is a preclinical, next-generation ADC targeting Trop2 on solid tumors, serving as Akari's lead candidate and reflecting its focus on innovative cancer therapies.

COMPETITORS

COMPETITOR
ANNX COMPARE
BCRX COMPARE
OMER COMPARE
REGN COMPARE

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
27
TOP 12 OF 27 · RANKED BY POSITION SIZE
Armistice Capital, LLC
2.7M sh · $787.23K
Cresset Asset Management, LLC
822.5K sh · $830.69K
Warberg Asset Management LLC
308.3K sh · $88.71K
Vhcp Management, LLC
158.4K sh · $1.11M
Palo Alto Investors LP
146.0K sh · $42.2K
Hightower Advisors, LLC
79.2K sh · $22.9K
Jane Street Group, LLC
71.6K sh · $20.7K
Xtx Topco Ltd
49.0K sh · $14.17K
Ubs Group AG
32.9K sh · $9.5K
Omnia Family Wealth, LLC
28.4K sh · $28.72K
Cerity Partners LLC
23.6K sh · $23.88K
Virtu Financial LLC
22.5K sh · $22K

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book4
Overall Score3

INSIDER TRADES

★
OFFICER: INTERIM CFO
Farag Kameel D.
Purchase · 1.7K shares
2026-08-17
★
OFFICER: INTERIM CFO
Farag Kameel D.
Purchase · 1.1K shares
2026-07-16
★
DIRECTOR, 10 PERCENT OWNER:
Patel Samir Rashmikant
Purchase · 1.2K shares
2026-07-07
★
DIRECTOR, 10 PERCENT OWNER:
Patel Samir Rashmikant
Purchase · 5.8K shares
2026-07-07

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
2 GRADES IN THE LAST 12 MONTHS
Maxim Group BUY HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
REVB$1.05COMPARE
DRMA$1.34COMPARE
CDT$1.69COMPARE
XAGE$0.22COMPARE
PPBT$1.68COMPARE
PBM$4.21COMPARE
VINC$0.01COMPARE
SYRS$0.00COMPARE